Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645921 | 0.82 | ACACB (0.36) | ALDH1A1CHRM1 | |
| SCHEMBL20014334 | 0.82 | CHRM1 (0.32) | CHRM1 | |
| SCHEMBL15830066 | 0.79 | CHRM1 (0.31) | CHRM1 | |
| SCHEMBL3827759 | 0.78 | CHRM1 (0.35) | ALDH1A1CHRM1 | |
| SCHEMBL1832130 | 0.78 | CHRM1 (0.35) | ALDH1A1CHRM1 | |
| SCHEMBL12384299 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CHRM1CHRNB2CHRNA4 | |
| SCHEMBL13780927 | 0.78 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL1830717 | 0.76 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL24675303 | 0.76 | CHRNB2 (0.31) | ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL17383828 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014100719-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-8759379-B2 | Inhibitors of cytochrome P450 | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2384328-B1 | 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM INT (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | GILEAD SCIENCES, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175820-A1 | INHIBITORS OF CYTOCHROME P450 | CYP11B1, CYP11B2, CYP2F1 | ALDH1A1 168/4885CHRM1 3733/4885CHRNB2 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.